

Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Enzyme Type (Alglucosidase Alfa, Agalsidase Beta, Imiglucerase, Idursulfase, Galsulfase, Velaglucerase Alfa, and Other Enzymes), Therapeutic Conditions (Gaucher's Disease, Fabry's Disease, MPS, Pompe's Disease, SCID, and Other Therapeutic Conditions), Route of Administration (Parenteral and Oral), and End User (Hospitals, Infusion Centers, and Others)

Market Report | 2022-07-18 | 226 pages | The Insight Partners

AVAILABLE LICENSES:

- Single User Price \$4550.00
- Site Price \$6550.00
- Enterprise Price \$8550.00

Report description:

The enzyme replacement therapy market is expected to grow from US\$ 9,673.39 million in 2021 to US\$ 15,184.70 million by 2028; it is estimated to grow at a CAGR of 6.8% from 2022 to 2028.

The report highlights trends prevailing in the market and factors driving the market growth. The growth of the global enzyme replacement therapy market is attributed to the rising prevalence of lysosomal storage diseases (LSDs) and rapid regulatory approval with other marketing benefits for drug with orphan drug designation. However, cutthroat competition among market players hinders the overall market growth.

Enzyme replacement therapy (ERT) is performed to treat congenital enzyme deficiencies by using enzyme or protein having enzymatic activity. Animal, human, and recombinant engineered enzymes are a few sources of enzyme required for treatment. The therapy is generally applied in rare and lysosomal storage diseases, including Pompe's disease, Fabry's disease, Gaucher's disease, Tay-Sachs disease, and Hurler syndrome. The most common ERT method is IV infusions, in which the replacement enzyme is administered directly into the bloodstream through a controlled drip of fluids.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

European Medicines Agency (EMA) approves orphan drugs. For instance, according to EMA, if a product that has an orphan drug designation receives EMA marketing approval for the indication for which it has such designation, the product is entitled to orphan market exclusivity. It means the EMA may not approve any other application to market a similar drug for the same indication for 10 years.

Furthermore, in March 2016, the EMA launched the Priority Medicines ("PRIME") scheme to facilitate the development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIME scheme also provides several benefits to drug producers; once a candidate medicine is selected for PRIME. Below mentioned are the benefits provided by the EMA:

- Appoint a rapporteur from the Committee for Medicinal Products for Human Use (CHMP) and help to build knowledge ahead of a marketing-authorization application
- Early and proactive regulatory dialogue with the EMA to guide the overall development plan and regulatory strategy;
- Provide scientific advice at key development milestones, involving additional stakeholders such as health-technology-assessment bodies, to facilitate quicker access for patients to the new medicine;
- Confirm potential for accelerated assessment at the time of an application for marketing authorization.

Therefore, owing to the benefit and incentives associated with drugs designated as orphan drugs, key players operating in the market are putting efforts into developing drugs for orphan diseases. For instance, Amicus Therapeutics, Inc. recently obtained an orphan medicinal product designation in Europe from the EMA for Galafold to treat Fabry disease and the combination product, ATB200/AT2221, for treating Pompe disease. Additionally, in September 2020, Amicus Therapeutics, Inc. was granted PRIME designation for AT-GTX-501, therapy for CLN6 Batten disease.

Thus, the rapid regulatory approval with other marketing benefits for the drug with orphan drug designation is driving the market growth.

Based on enzyme type, the global enzyme replacement therapy market is segmented into alglucosidase alfa, agalsidase beta, imiglucerase, idursulfase, galsulfase, velaglucerase alfa, and other enzymes. In 2021, the other enzymes segment accounted for the largest market share. The same segment is expected to register the highest CAGR in the market from 2022 to 2028. Based on therapeutic conditions, the global enzyme replacement therapy market is segmented into Gaucher's disease, Fabry's disease, Pompe's disease, SCID, MPS, and other therapeutic conditions. The Gaucher's disease segment held the largest market share in 2021 and is expected to register the highest CAGR during the forecast period. Based on route of administration, the global enzyme replacement therapy market is bifurcated into parenteral and oral. The parenteral segment held a larger market share in 2021 and is anticipated to register a higher CAGR during the forecast period. Based on end user, the global enzyme replacement therapy market is segmented into hospitals, infusion centers, and others. The hospitals segment held the largest market share in 2021. However, the infusion centers segment is expected to register the highest CAGR during the forecast period.

Impact of COVID-19 Pandemic on Global Enzyme Replacement Therapy Market

The COVID-19 pandemic significantly affected the global healthcare system. To combat the spread of SAR-CoV-2 virus, governments imposed stringent policies to prevent and reduce the infection and mortality rates. According to the Department of Emergency Medicine, in many cities across various countries in North America, emergency department (ED) visits decreased by ~40% in 2020. Moreover, outpatient appointments and elective treatments were postponed or replaced by telemedicine practices.

Moreover, the interruption of ERT during the COVID-19 pandemic may have significant consequences. Due to restrictions on hospital visits during the pandemic, many scheduled ERTs were disrupted, which led to severity of conditions in LSDs patients. Also, lysosomal storage diseases are considered to be high risk because of respiratory, renal, and cardiac involvement. For instance, in 2021, a sample survey conducted by some doctors from Sir Ganga Ram Hospital, India, results of which were published in Indian Pediatrics, offered a glimpse into the crisis. The survey revealed that of the 26 patients suffering from lysosomal storage disorders and receiving ERT at the hospital, 20 (77%) had significant interruption in their treatment, with an average eight missed doses. Of the 20 patients who missed multiple doses, 13 (65%) could not collect the medicine from the tertiary care center due to lack of transportation as lockdown was in place, while for two (10%), the medicine import was delayed.

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Thus, such interruptions in ERT increased the suffering of LSDs patients and impacted the enzyme replacement therapy market negatively.

Various organic and inorganic strategies are adopted by companies operating in the global enzyme replacement therapy market. The organic strategies mainly include product launches and product approvals. Further, inorganic growth strategies witnessed in the market are acquisitions, collaborations, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, thereby contributing to the overall market growth. Further, acquisition and partnership strategies help the market players in strengthening their customer base and expanding their product portfolios. A few of the significant developments by key players in the global enzyme replacement therapy market are listed below.

-□ In May 2022, AbbVie and Cugene Inc., a clinical-stage biotechnology company focused on developing next-generation precision immunology and oncology medicines to treat autoimmune disease and cancer, announced an exclusive worldwide license option agreement for CUG252, a potential best-in-class Treg-selective IL-2 mutein, as well as other novel IL-2 muteins, for the potential treatment of autoimmune and inflammatory diseases.

-□ In August 2021, the US Food and Drug Administration (FDA) approved Nexviazyme (avalglucosidase alfa-ngpt) for the treatment of patients aged one year and above suffering from late-onset Pompe disease, a progressive and debilitating muscle disorder that impairs a person's ability to move and breathe. Nexviazyme is an ERT designed to specifically target the mannose-6-phosphate (M6P) receptor, the key pathway for cellular uptake of ERT in Pompe disease. Nexviazyme has been shown in clinical trials to provide patients with improvements in respiratory function and walking distance.

A few major primary and secondary sources referred to while preparing the report on the global enzyme replacement therapy market are the National Health and Medical Research Council (NHMRC), the Government of Canada, and the Bioprocessing Technology Institute (BTI).

Table of Contents:

TABLE OF CONTENTS

1. Introduction
 - 1.1 Scope of the Study
 - 1.2 The Insight Partners Research Report Guidance
 - 1.3 Market Segmentation
 - 1.3.1 Global Enzyme Replacement Therapy Market - By Enzyme Type
 - 1.3.2 Global Enzyme Replacement Therapy Market - By Therapeutic Conditions
 - 1.3.3 Global Enzyme Replacement Therapy Market - By Route of Administration
 - 1.3.4 Global Enzyme Replacement Therapy Market - By End User
 - 1.3.5 Global Enzyme Replacement Therapy Market - By Geography
2. Enzyme Replacement Therapy Market- Key Takeaways
3. Research Methodology
 - 3.1 Coverage
 - 3.2 Secondary Research
 - 3.3 Primary Research
4. Global Enzyme Replacement Therapy Market - Market Landscape
 - 4.1 Overview
 - 4.2 PEST Analysis
 - 4.2.1 North America - PEST Analysis
 - 4.2.2 Europe - PEST Analysis
 - 4.2.3 Asia Pacific - PEST Analysis
 - 4.2.4 Middle East & Africa - PEST Analysis
 - 4.2.5 South & Central America - PEST Analysis
 - 4.3 Expert Opinion

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5. Enzyme Replacement Therapy Market - Key Market Dynamics
 - 5.1 Market Drivers
 - 5.1.1 Rising Prevalence of Lysosomal Storage Diseases (LSDs)
 - 5.1.2 Rapid Regulatory Approval with Other Benefits for Drug with Orphan Drug Designation
 - 5.2 Market Restraints
 - 5.2.1 Cutthroat Competition among Market Players
 - 5.3 Market Opportunities
 - 5.3.1 Increasing Partnerships and Collaborations to Synergize the Business
 - 5.4 Future Trends
 - 5.4.1 Innovative Developments in ERT
 - 5.5 Impact Analysis
- 6. Enzyme Replacement Therapy Market- Global Analysis
 - 6.1 Global Enzyme Replacement Therapy Market Revenue Forecast and Analysis
 - 6.1.1 Global Enzyme Replacement Therapy Market Revenue Forecast and Analysis
 - 6.1.2 Global Enzyme Replacement Therapy Market - Market Potential Analysis, By Region
 - 6.2 Market Share Analysis of Key Players in Enzyme Replacement Therapy Market
 - 6.2.1 Company Analysis
 - 6.2.2 Growth Strategy Analysis
 - 6.2.3 Performance of Key Players
 - 6.2.3.1 Sanofi S.A.
 - 6.2.3.2 BioMarin Pharmaceutical Inc.
- 7. Global Enzyme Replacement Therapy Market Revenue and Forecasts To 2028- by Enzyme Type
 - 7.1 Overview
 - 7.2 Global Enzyme Replacement Therapy Market, By Enzyme Type 2021 & 2028 (%)
 - 7.3 Alglucosidase Alfa
 - 7.3.1 Overview
 - 7.3.2 Alglucosidase Alfa Revenue and Forecast to 2028 (US\$ Million)
 - 7.4 Agalsidase Beta
 - 7.4.1 Overview
 - 7.4.2 Agalsidase Beta - Revenue and Forecast to 2028 (US\$ Million)
 - 7.5 Imiglucerase
 - 7.5.1 Overview
 - 7.5.2 Imigluceras - Revenue and Forecast to 2028 (US\$ Million)
 - 7.6 Idursulfase
 - 7.6.1 Overview
 - 7.6.2 Idursulfase - Revenue and Forecast to 2028 (US\$ Million)
 - 7.7 Galsulfase
 - 7.7.1 Overview
 - 7.7.2 Galsulfase - Revenue and Forecast to 2028 (US\$ Million)
 - 7.8 Velaglucerase Alfa
 - 7.8.1 Overview
 - 7.8.2 Velaglucerase Alfa - Revenue and Forecast to 2028 (US\$ Million)
 - 7.9 Other Enzymes
 - 7.9.1 Overview
 - 7.9.2 Other Enzymes - Revenue and Forecast to 2028 (US\$ Million)
- 8. Enzyme Replacement Therapy Market Analysis And Forecasts To 2028 - By Therapeutic Conditions
 - 8.1 Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.2 Global Enzyme Replacement Therapy Market, By Therapeutic Conditions 2021 & 2028 (%)
- 8.3 Gaucher's Disease
 - 8.3.1 Overview
 - 8.3.2 Gaucher's Disease - Market Revenue and Forecast to 2028 (US\$ Million)
- 8.4 Fabry's Disease
 - 8.4.1 Overview
 - 8.4.2 Fabry's Disease - Market Revenue and Forecast to 2028 (US\$ Million)
- 8.5 Mucopolysaccharidosis (MPS)
 - 8.5.1 Overview
 - 8.5.2 MPS - Market Revenue and Forecast to 2028 (US\$ Million)
- 8.6 Pompe's Disease
 - 8.6.1 Overview
 - 8.6.2 Pompe's Disease - Market Revenue and Forecast to 2028 (US\$ Million)
- 8.7 SCID
 - 8.7.1 Overview
 - 8.7.2 SCID - Market Revenue and Forecast to 2028 (US\$ Million)
- 8.8 Other Therapeutic Conditions
 - 8.8.1 Overview
 - 8.8.2 Other Therapeutic Conditions - Market Revenue and Forecast to 2028 (US\$ Million)
- 9. Enzyme Replacement Therapy Market Analysis And Forecasts To 2028 - By Route of Administration
 - 9.1 Overview
 - 9.2 Global Enzyme Replacement Therapy Market, By Route of Administration 2021 & 2028 (%)
 - 9.3 Parenteral
 - 9.3.1 Overview
 - 9.3.2 Parenteral - Market Revenue and Forecast to 2028 (US\$ Million)
 - 9.4 Oral
 - 9.4.1 Overview
 - 9.4.2 Oral - Market Revenue and Forecast to 2028 (US\$ Million)
- 10. Global Enzyme Replacement Therapy Market Analysis- By End User
 - 10.1 Overview
 - 10.2 Global Enzyme Replacement Therapy Market, By End User 2021 & 2028 (%)
 - 10.3 Hospitals
 - 10.3.1 Overview
 - 10.3.2 Hospitals - Market Revenue And Forecasts To 2028 (US\$ Million)
 - 10.4 Infusion Centers
 - 10.4.1 Overview
 - 10.4.2 Infusion Centers - Market Revenue And Forecasts To 2028 (US\$ Million)
 - 10.5 Others
 - 10.5.1 Overview
 - 10.5.2 Others - Market Revenue And Forecasts To 2028 (US\$ Million)
- 11. Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 - Geographical Analysis
 - 11.1 North America: Enzyme Replacement Therapy Market
 - 11.1.1 Overview
 - 11.1.2 North America: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.1.3 North America: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US\$ Million)
 - 11.1.4 North America: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US\$ Million)
 - 11.1.5 North America: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US\$ Million)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.1.6 North America: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US\$ Million)
- 11.1.7 North America: Enzyme Replacement Therapy Market, by Country, 2021 & 2028 (%)
 - 11.1.7.1 US: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.1.7.1.1 Overview
 - 11.1.7.1.2 US: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.1.7.1.3 US: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US\$ Million)
 - 11.1.7.1.4 US: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US\$ Million)
 - 11.1.7.1.5 US: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US\$ Million)
 - 11.1.7.1.6 US: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US\$ Million)
 - 11.1.7.2 Canada: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.1.7.2.1 Overview
 - 11.1.7.2.2 Canada: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.1.7.2.3 Canada: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US\$ Million)
 - 11.1.7.2.4 Canada: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US\$ Million)
 - 11.1.7.2.5 Canada: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US\$ Million)
 - 11.1.7.2.6 Canada: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US\$ Million)
 - 11.1.7.3 Mexico: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.1.7.3.1 Overview
 - 11.1.7.3.2 Mexico: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.1.7.3.3 Mexico: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US\$ Million)
 - 11.1.7.3.4 Mexico: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US\$ Million)
 - 11.1.7.3.5 Mexico: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US\$ Million)
 - 11.1.7.3.6 Mexico: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US\$ Million)
- 11.2 Europe: Enzyme Replacement Therapy Market
 - 11.2.1 Overview
 - 11.2.2 Europe: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.2.3 Europe: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US\$ Million)
 - 11.2.4 Europe: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US\$ Million)
 - 11.2.5 Europe: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US\$ Million)
 - 11.2.6 Europe: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US\$ Million)
 - 11.2.7 Europe: Enzyme Replacement Therapy Market, by Country, 2021 & 2028 (%)
 - 11.2.7.1 Germany: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.2.7.1.1 Overview
 - 11.2.7.1.2 Germany: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.2.7.1.3 Germany: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US\$ Million)
 - 11.2.7.1.4 Germany: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US\$ Million)
 - 11.2.7.1.5 Germany: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US\$ Million)
 - 11.2.7.1.6 Germany: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US\$ Million)
 - 11.2.7.2 UK: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.2.7.2.1 Overview
 - 11.2.7.2.2 UK: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.2.7.2.3 UK: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US\$ Million)
 - 11.2.7.2.4 UK: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US\$ Million)
 - 11.2.7.2.5 UK: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US\$ Million)
 - 11.2.7.2.6 UK: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US\$ Million)
 - 11.2.7.3 France: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.2.7.3.1 Overview

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.2.7.3.2 France: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.2.7.3.3 France: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US\$ Million)
- 11.2.7.3.4 France: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US\$ Million)
- 11.2.7.3.5 France: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US\$ Million)
- 11.2.7.3.6 France: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US\$ Million)
- 11.2.7.4 Italy: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.2.7.4.1 Overview
- 11.2.7.4.2 Italy: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.2.7.4.3 Italy: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US\$ Million)
- 11.2.7.4.4 Italy: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US\$ Million)
- 11.2.7.4.5 Italy: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US\$ Million)
- 11.2.7.4.6 Italy: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US\$ Million)
- 11.2.7.5 Spain: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.2.7.5.1 Overview
- 11.2.7.5.2 Spain: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.2.7.5.3 Spain: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US\$ Million)
- 11.2.7.5.4 Spain: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US\$ Million)
- 11.2.7.5.5 Spain: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US\$ Million)
- 11.2.7.5.6 Spain: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US\$ Million)
- 11.2.7.6 Rest of Europe: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.2.7.6.1 Overview
- 11.2.7.6.2 Rest of Europe: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
- 11.2.7.6.3 Rest of Europe: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (US\$ Million)
- 11.2.7.6.4 Rest of Europe: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (US\$ Million)
- 11.2.7.6.5 Rest of Europe: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (US\$ Million)
- 11.2.7.6.6 Rest of Europe: Enzyme Replacement Therapy Market, by End User, 2019-2028 (US\$ Million)
- 11.3 Asia Pacific: Enzyme Replacement Therapy Market Revenue and Forecasts To 2028
- 11.3.1 Overview
- 11.3.2 Asia Pacific: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 (US\$ Million)
- 11.3.3 Asia Pacific: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Enzyme Type (US\$ Million)
- 11.3.4 Asia Pacific: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Therapeutic Conditions (US\$ Million)
- 11.3.5 Asia Pacific: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Route of Administration (US\$ Million)
- 11.3.6 Asia Pacific: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By End User (US\$ Million)
- 11.3.7 Asia Pacific: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Country (%)
- 11.3.7.1 Japan: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 (US\$ Million)
- 11.3.7.1.1 Overview
- 11.3.7.1.2 Japan: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 (US\$ Million)
- 11.3.7.1.3 Japan: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Enzyme Type (US\$ Million)
- 11.3.7.1.4 Japan: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Therapeutic Conditions (US\$ Million)
- 11.3.7.1.5 Japan: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Route of Administration (US\$ Million)
- 11.3.7.1.6 Japan: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By End User (US\$ Million)
- 11.3.7.2 China: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 (US\$ Million)
- 11.3.7.2.1 Overview
- 11.3.7.2.2 China: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 (US\$ Million)
- 11.3.7.2.3 China: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Enzyme Type (US\$ Million)
- 11.3.7.2.4 China: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Therapeutic Conditions (US\$ Million)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.3.7.2.5 China: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Route of Administration (US\$ Million)
- 11.3.7.2.6 China: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By End User (US\$ Million)
- 11.3.7.3 India Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 (US\$ Million)
 - 11.3.7.3.1 Overview
 - 11.3.7.3.2 India: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 (US\$ Million)
 - 11.3.7.3.3 India: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Enzyme Type (US\$ Million)
 - 11.3.7.3.4 India: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Therapeutic Conditions (US\$ Million)
 - 11.3.7.3.5 India: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Route of Administration (US\$ Million)
 - 11.3.7.3.6 India: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By End User (US\$ Million)
- 11.3.7.4 Australia: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 (US\$ Million)
 - 11.3.7.4.1 Overview
 - 11.3.7.4.2 Australia: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 (US\$ Million)
 - 11.3.7.4.3 Australia: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Enzyme Type (US\$ Million)
 - 11.3.7.4.4 Australia: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Therapeutic Conditions (US\$ Million)
 - 11.3.7.4.5 Australia: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Route of Administration (US\$ Million)
 - 11.3.7.4.6 Australia: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By End User (US\$ Million)
- 11.3.7.5 South Korea: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 (US\$ Million)
 - 11.3.7.5.1 Overview
 - 11.3.7.5.2 South Korea: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028 (US\$ Million)
 - 11.3.7.5.3 South Korea: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Enzyme Type (US\$ Million)
 - 11.3.7.5.4 South Korea: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Therapeutic Conditions (US\$ Million)
 - 11.3.7.5.5 South Korea: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Route of Administration (US\$ Million)
 - 11.3.7.5.6 South Korea: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By End User (US\$ Million)
- 11.3.7.6 Rest of Asia Pacific: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.3.7.6.1 Overview
 - 11.3.7.6.2 Rest of Asia Pacific: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (US\$ Million)
 - 11.3.7.6.3 Rest of Asia Pacific: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Enzyme Type (US\$ Million)
 - 11.3.7.6.4 Rest of Asia Pacific: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Therapeutic Conditions (US\$ Million)
 - 11.3.7.6.5 Rest of Asia Pacific: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By Route of Administration (US\$ Million)
 - 11.3.7.6.6 Rest of Asia Pacific: Enzyme Replacement Therapy Market Revenue and Forecasts to 2028, By End User (US\$ Million)
- 11.4 South & Central America: Enzyme Replacement Therapy Market
 - 11.4.1 Overview
 - 11.4.2 South and Central America: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (USD Million)
 - 11.4.3 South and Central America: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (USD Million)
 - 11.4.4 South and Central America: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (USD Million)
 - 11.4.5 South and Central America: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (USD Million)
 - 11.4.6 South and Central America: Enzyme Replacement Therapy Market, by End User, 2019-2028 (USD Million)
 - 11.4.7 South and Central America: Enzyme Replacement Therapy Market, by country, 2021 & 2028 (%)
 - 11.4.7.1 Brazil: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (USD Million)
 - 11.4.7.1.1 Brazil: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (USD Million)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.4.7.1.2 Brazil: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (USD Million)
- 11.4.7.1.3 Brazil: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (USD Million)
- 11.4.7.1.4 Brazil: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (USD Million)
- 11.4.7.1.5 Brazil: Enzyme Replacement Therapy Market, by End User, 2019-2028 (USD Million)
- 11.4.7.2 Argentina: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (USD Million)
 - 11.4.7.2.1 Argentina: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (USD Million)
 - 11.4.7.2.2 Argentina: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (USD Million)
 - 11.4.7.2.3 Argentina: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (USD Million)
 - 11.4.7.2.4 Argentina: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (USD Million)
 - 11.4.7.2.5 Argentina: Enzyme Replacement Therapy Market, by End User, 2019-2028 (USD Million)
- 11.4.7.3 Rest of South and Central America: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (USD Million)
 - 11.4.7.3.1 Rest of South and Central America: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (USD Million)
 - 11.4.7.3.2 Rest of South and Central America: Enzyme Replacement Therapy Market, by Enzyme Type, 2019-2028 (USD Million)
 - 11.4.7.3.3 Rest of South and Central America: Enzyme Replacement Therapy Market, by Therapeutic Conditions, 2019-2028 (USD Million)
 - 11.4.7.3.4 Rest of South and Central America: Enzyme Replacement Therapy Market, by Route of Administration, 2019-2028 (USD Million)
 - 11.4.7.3.5 Rest of South and Central America: Enzyme Replacement Therapy Market, by End User, 2019-2028 (USD Million)
- 11.5 Middle East & Africa Enzyme Replacement Therapy Market
 - 11.5.1 Overview
 - 11.5.2 Middle East & Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US\$ Million)
 - 11.5.3 Middle East & Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, by Enzyme Type (US\$ Million)
 - 11.5.4 Middle East & Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, by Therapeutic Conditions (US\$ Million)
 - 11.5.5 Middle East & Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, by Route of Administration (US\$ Million)
 - 11.5.6 Middle East & Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, by End User (US\$ Million)
 - 11.5.7 Middle East & Africa Enzyme Replacement Therapy Market Revenue and Forecast to 2028, by Country (%)
 - 11.5.7.1 Saudi Arabia: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (USD Million)
 - 11.5.7.1.1 Overview
 - 11.5.7.1.2 Saudi Arabia Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US\$ Million)
 - 11.5.7.1.3 Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Enzyme Type (US\$ Million)
 - 11.5.7.1.4 Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Therapeutic Conditions (US\$ Million)
 - 11.5.7.1.5 Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Route of Administration (US\$ Million)
 - 11.5.7.1.6 Saudi Arabia: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By End User (US\$ Million)
 - 11.5.7.2 South Africa: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (USD Million)
 - 11.5.7.2.1 Overview
 - 11.5.7.2.2 South Africa Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US\$ Million)
 - 11.5.7.2.3 South Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Enzyme Type (US\$ Million)
 - 11.5.7.2.4 South Africa: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Therapeutic Conditions (US\$ Million)
 - 11.5.7.2.5 South Africa: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Route of Administration (US\$ Million)
 - 11.5.7.2.6 South Africa: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By End User (US\$ Million)
 - 11.5.7.3 UAE: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (USD Million)

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 11.5.7.3.1 Overview
- 11.5.7.3.2 UAE: Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US\$ Million)
- 11.5.7.3.3 UAE: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Enzyme Type (US\$ Million)
- 11.5.7.3.4 UAE: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Therapeutic Conditions (US\$ Million)
- 11.5.7.3.5 UAE: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Route of Administration (US\$ Million)
- 11.5.7.3.6 UAE: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By End User (US\$ Million)
- 11.5.7.4 Rest of the Middle East and Africa: Enzyme Replacement Therapy Market - Revenue and Forecast to 2028 (USD Million)
- 11.5.7.4.1 Overview
- 11.5.7.4.2 Rest of the Middle East and Africa Enzyme Replacement Therapy Market Revenue and Forecast to 2028 (US\$ Million)
- 11.5.7.4.3 Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast to 2028, By Enzyme Type (US\$ Million)
- 11.5.7.4.4 Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Therapeutic Conditions (US\$ Million)
- 11.5.7.4.5 Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By Route of Administration (US\$ Million)
- 11.5.7.4.6 Rest of the Middle East and Africa: Enzyme Replacement Therapy Market Revenue and Forecast To 2028, By End User (US\$ Million)
- 12. Impact Of COVID-19 Pandemic on Enzyme Replacement Therapy Market
- 12.1 North America: Impact Assessment of COVID-19 Pandemic
- 12.2 Europe: Impact Assessment of COVID-19 Pandemic
- 12.3 Asia-Pacific: Impact Assessment of COVID-19 Pandemic
- 12.4 South and Central America: Impact Assessment of COVID-19 Pandemic
- 12.5 Middle East and Africa: Impact Assessment of COVID-19 Pandemic
- 13. Enzyme Replacement Therapy Market-Industry Landscape
- 13.1 Overview
- 13.2 Growth Strategies in the Enzyme Replacement Therapy Market
- 13.3 Inorganic Growth Strategies
- 13.3.1 Overview
- 13.4 Organic Growth Strategies
- 13.4.1 Overview
- 14. Company Profiles
- 14.1 Takeda Pharmaceutical Company Limited
- 14.1.1 Key Facts
- 14.1.2 Business Description
- 14.1.3 Products and Services
- 14.1.4 Financial Overview
- 14.1.5 SWOT Analysis
- 14.1.6 Key Developments
- 14.2 Sanofi
- 14.2.1 Key Facts
- 14.2.2 Business Description
- 14.2.3 Products and Services
- 14.2.4 Financial Overview
- 14.2.5 SWOT Analysis
- 14.2.6 Key Developments
- 14.3 AbbVie Inc.
- 14.3.1 Key Facts

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.3.2 Business Description
- 14.3.3 Products and Services
- 14.3.4 Financial Overview
- 14.3.5 SWOT Analysis
- 14.3.6 Key Developments
- 14.4 BioMarin Pharmaceutical Inc.
- 14.4.1 Key Facts
- 14.4.2 Business Description
- 14.4.3 Products and Services
- 14.4.4 Financial Overview
- 14.4.5 SWOT Analysis
- 14.4.6 Key Developments
- 14.5 Amicus Therapeutics
- 14.5.1 Key Facts
- 14.5.2 Business Description
- 14.5.3 Products and Services
- 14.5.4 Financial Overview
- 14.5.5 SWOT Analysis
- 14.5.6 Key Developments
- 14.6 Alexion Pharmaceuticals, Inc.(AstraZeneca)
- 14.6.1 Key Facts
- 14.6.2 Business Description
- 14.6.3 Products and Services
- 14.6.4 Financial Overview
- 14.6.5 WOT Analysis
- 14.6.6 Key Developments
- 14.7 Janssen Pharmaceuticals (Johnson & Johnson Services, Inc.)
- 14.7.1 Key Facts
- 14.7.2 Business Description
- 14.7.3 Products and Services
- 14.7.4 Financial Overview
- 14.7.5 SWOT Analysis
- 14.7.6 Key Developments
- 14.8 Recordati S.p.A.
- 14.8.1 Key Facts
- 14.8.2 Business Description
- 14.8.3 Products and Services
- 14.8.4 Financial Overview
- 14.8.5 SWOT Analysis
- 14.8.6 Key Developments
- 14.9 Pfizer Inc.
- 14.9.1 Key Facts
- 14.9.2 Business Description
- 14.9.3 Products and Services
- 14.9.4 Financial Overview
- 14.9.5 SWOT Analysis
- 14.9.6 Key Developments

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 14.10 CHIESI Farmaceutici S.p.A.
- 14.10.1 Key Facts
- 14.10.2 Business Description
- 14.10.3 Products and Services
- 14.10.4 Financial Overview
- 14.10.5 SWOT Analysis
- 14.10.6 Key Developments
- 15. Appendix
- 15.1 About The Insight Partners
- 15.2 Glossary of Terms

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Enzyme Replacement Therapy Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Enzyme Type (Alglucosidase Alfa, Agalsidase Beta, Imiglucerase, Idursulfase, Galsulfase, Velaglucerase Alfa, and Other Enzymes), Therapeutic Conditions (Gaucher's Disease, Fabry's Disease, MPS, Pompe's Disease, SCID, and Other Therapeutic Conditions), Route of Administration (Parenteral and Oral), and End User (Hospitals, Infusion Centers, and Others)

Market Report | 2022-07-18 | 226 pages | The Insight Partners

To place an Order with Scotts International:

- Print this form
- Complete the relevant blank fields and sign
- Send as a scanned email to support@scotts-international.com

ORDER FORM:

Select license	License	Price
	Single User Price	\$4550.00
	Site Price	\$6550.00
	Enterprise Price	\$8550.00
		VAT
		Total

*Please circle the relevant license option. For any questions please contact support@scotts-international.com or 0048 603 394 346.

** VAT will be added at 23% for Polish based companies, individuals and EU based companies who are unable to provide a valid EU Vat Numbers.

Email*	<input type="text"/>	Phone*	<input type="text"/>
First Name*	<input type="text"/>	Last Name*	<input type="text"/>
Job title*	<input type="text"/>		

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

Company Name*	<input type="text"/>	EU Vat / Tax ID / NIP number*	<input type="text"/>
Address*	<input type="text"/>	City*	<input type="text"/>
Zip Code*	<input type="text"/>	Country*	<input type="text"/>
		Date	<input type="text" value="2026-06-09"/>
		Signature	<input type="text"/>